Navigation Links
U.S. Study Shows Significant Improvement for Patients Suffering from Excessive Sweating with Topical Antiperspirant
Date:5/15/2009

ALBANY, N.Y., May 15 /PRNewswire/ -- Valeo Pharma announced today a new study recently published that demonstrated the efficacy and safety of Hydrosal(R), a novel high strength topical antiperspirant with 15% aluminum chloride and 2% salicylic acid in proprietary gel base for patients with moderate-to-severe hyperhidrosis (excessive sweating).

The study, conducted by Katherine Flanagan, MD and Dee Anna Glaser, MD at the Department of Dermatology at Saint Louis University School of Medicine, was published in the May issue of the Journal of Drugs in Dermatology (JDD). Of the thirty patients who were enrolled, 43% had tried high-strength antiperspirants previously. Patients were given Hydrosal and monitored at 4 and 12 weeks for efficacy and tolerability. They were instructed to apply a small amount of the gel at bedtime for seven days and twice per week or as tolerated thereafter.

Overall, 70% of participants demonstrated significant improvement with satisfaction of treatment and Hydrosal was well-tolerated with minimal side effects. Patients who had previously failed other high-strength antiperspirants also reported similar success. They also experienced significant improvements in quality of life including improvement in social and professional situations.

"The key to Hydrosal's effectiveness is the gel base -- it is unique and helps balance high efficacy and tolerability for patients with moderate to severe hyperhidrosis. Valeo is extremely pleased that these results have shown a significant improvement in the quality of life for these patients, so they can enjoy activities more and not have to worry about their excessive sweating," stated Steve Saviuk, President of Valeo Pharma.

To learn more about Hydrosal Professional, please visit www.hydrosalpro.com or contact Valeo Pharma at 866 694-0150.

To see press release go to http://myprgenie.com/1897


'/>"/>
SOURCE Valeo Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent Care ... MD Now’s 28th facility overall and marks the urgent care center's eighth location in ... North of The Falls shopping mall. The new clinic offers a wide array of ...
(Date:6/23/2017)... ... ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an upcoming episode ... Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for more info. ... 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in science and ...
(Date:6/23/2017)... Chicago, IL (PRWEB) , ... June 23, 2017 ... ... insurance management assistance and financial planning services to communities in the greater Chicago ... Children’s Association to offer assistance to underprivileged youth in Chicago. , Founded in ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, ... area with access to asset protection and financial planning services, is teaming up ... improving the lives of children with cancer and other chronic diseases. , The ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... is pleased to welcome Whipple & Company as its newest Partner Firm. Headquartered ... of balancing their clients’ risk while tailoring optimized benefit packages that strengthen the ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology: